HITLAB Partners with LifeAhead to De-Risk FDA Submission Through Physician-Centered Usability Validation
New York, NY — December 23, 2025 — HITLAB, a leading authority in digital health validation and regulatory evidence generation, announced a strategic partnership with LifeAhead to support physician-centered usability testing and FDA readiness as LifeAhead advances toward regulatory submission.
The collaboration is designed to materially reduce regulatory, execution, and timeline risk—one of the most common causes of delay and value erosion in digital health companies approaching FDA review. HITLAB will lead a comprehensive, FDA-aligned usability validation program that produces regulator-ready evidence and documentation, helping LifeAhead move through the submission process with greater speed, confidence, and predictability.
HITLAB’s scope includes end-to-end study design, recruitment, and execution of usability testing with OB/GYN and Reproductive Endocrinology & Infertility (REI) physicians—the core clinical users of the platform. The program incorporates clearly defined inclusion criteria, geographic diversity targets, structured onboarding, and disciplined study logistics to ensure results reflect real-world clinical workflows and FDA expectations.
Following testing, HITLAB will translate findings into a formal usability engineering report suitable for FDA submission and support preparation of the broader regulatory package, including materials required for FDA meetings. This approach reduces the likelihood of costly remediation cycles, additional studies, or review delays post-submission.
“From an investor perspective, regulatory uncertainty is one of the largest sources of downside risk in digital health,” said Dr. Stan Kachnowski, Chair of HITLAB. “This partnership is about eliminating ambiguity early—generating the right usability evidence, in the right format, at the right time—so LifeAhead can protect valuation and maintain momentum through FDA review.”
For LifeAhead, the partnership strengthens its regulatory posture while signaling operational discipline and capital efficiency to current and prospective investors. For HITLAB, it reinforces its role as a validation partner focused on converting innovation into investable, regulator-ready assets.
About HITLAB
About LifeAhead
LifeAhead develops evidence-based forecasting solutions for women’s health, helping clinicians and patients anticipate and manage key reproductive milestones like menopause and patient-centered design, with a focus on scalable, evidence-based innovation.
Share the article:
Learn more about
